I don't know about the timeline but Biogen is usually pretty fast with that sort of thing. As far as it's prospects go, part of the problem is that a lot of it's sales will come at the expense of Tecfidera sales. It will probably see some additional sales due to the lesser gastro issues but it won't be a huge thing. It might also in a sense extend the patent of Tecfidera/Vumerity.
Not much buzz within Biogen about it...at least from what I have noticed. It will be a challenge. Insurance companies apt to put a block on it given minimal difference
